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DRUG COSTS ATTHE END OF LIFE
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Leuven, Leuven, Belgium
OBJECTIVES: In a context of ageing populations and rising
health care costs, it is important to explore health care costs at
the end of life. The aim of this study is to quantify drug costs of
patients who died at the University Hospitals Leuven in Belgium
in 2006. METHODS: This retrospective, cross-sectional cost
analysis measured drug costs related to the hospital stay during
which patients died at University Hospitals Leuven in 2006.
Drugs were classiﬁed at level 1 of the Anatomical Therapeutic
Chemical (ATC) classiﬁcation system. Drug resource utilisation
was valued at unit costs pertaining to University Hospitals
Leuven. The price year was 2007. Associations between drug
costs and patient characteristics were investigated using the
Mann-Whitney U-test. RESULTS: In total, 1462 patients died
during their hospital stay at University Hospitals Leuven in 2006.
Total drug costs related to their ﬁnal hospital stay amounted to
2,970,457€. Median costs per patient were 576€ (0€–48,236€).
There was no association between drug costs per patient and
gender (p = 0.063). Median costs per patient were higher for
patients aged under 68 years (837€) than for patients aged over
68 years (470€) (p < 0.001). Total drug costs were made up of
blood and blood organs (ATC level B, 33% of costs), anti-
infectives for systemic use (ATC level J, 31% of costs), nervous
system drugs (ATC level N, 7% of costs), systemic hormonal
preparations (ATC level H, 3% of costs), cardiovascular drugs
(ATC level C, 2% of costs), and various other drugs (24% of
costs). The 15 patients with the most expensive hospital stays
generated 16% of total drug costs. CONCLUSION: Drug costs
related to the hospital stay during which patients died were
substantial. Drug resource utilization primarily related to blood
and blood organs, and anti-infectives for systemic use.
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OBJECTIVES: Published cost effectiveness analyses of IVF are
generally based on clinical trial data, although costs and out-
comes may not be representative of usual practice. This analysis
evaluated the costs and outcomes of rFSH use in usual practice in
the UK. METHODS: Subjects were randomly selected from all
women undergoing IVF or Intracytoplasmic Sperm Injection
(ICSI) treatment between 2001–2007 at a single centre serving
NHS and private patients in England. Women were treated with
rFSH (Puregon, Organon) for ovarian stimulation, predomi-
nantly as part of an antagonist protocol. Per cycle rates of clinical
and ongoing pregnancy and live birth were calculated. The costs
of rFSH were calculated from pharmacy dispensing data at 2007
UK prices. RESULTS: Four hundred, nineteen women were
included, reporting 601 treatment cycles. Mean age was 36.3
years (range 21–49). The causes of infertility were: male factor
(43%); female factor (38%); unexplained or other (19%). The
clinical pregnancy rate was 35.9% (95% CI 32.2–40.0%),
ongoing pregnancy rate 25.0% (21.5–28.4%) and live birth rate
20.8% (17.7–24.1%). Mean duration of ovarian stimulation was
9.4 days (9.3–9.6 days). The mean per cycle rFSH dose pre-
scribed was 1816 units (1775–1863) and dispensed was 1960
units (1897–2012). Mean cost of rFSH per cycle was 661
(640–679). CONCLUSION: UK guidelines assume the
average per cycle FSH dose is 1750–2625, cost of drugs is1000
and total cost of the cycle is 2771. By substituting FSH use
derived from clinical practice, the cost per cycle could be reduced
by 12%. Further research will extend this work to other centres
and settings.
PIH6
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OBJECTIVES: To generate national estimates of inpatient costs,
length of stay (LOS), and probability of death among US pedi-
atric (17 years) hospitalizations for blunt or penetrating
trauma, stratiﬁed by injury severity and trauma center designa-
tion of the admitting facility. METHODS: Discharge data from
the 2002 HCUP Nationwide Inpatient Sample were analyzed for
55,561 pediatric hospital admissions (unweighted n = 11,566)
for blunt or penetrating trauma. An injury severity score (ISS)
was calculated for each admission using the ICDMAP90 soft-
ware; 4 mutually exclusive categories corresponding to increas-
ing severity were identiﬁed. Data on admitting facilities’ trauma
center designation were obtained from the American Hospital
Association. Stays for patients admitted from or transferred to
another inpatient facility were excluded. Weighted estimates of
costs, LOS, and probability of death were calculated for each
stay. RESULTS: Most admissions (57.5%) were for low severity
injuries (ISS = 0–9); critical injuries (ISS = 25+) represented 8.5%
of admissions. Nearly half (44.9%) of all admissions were to
non-trauma centers; Level I, II, and III/IV trauma centers repre-
sented 29.9%, 19.5%, and 4.3% of admissions, respectively.
Overall, inpatient costs increased substantially with injury sever-
ity, ranging from $7,803 for low severity admissions to $34,135
for critical admissions. LOS and probability of death also
increased from low to critical injury severity (3.0 to 10.7 days,
0.5% to 23.9%, respectively). Costs, LOS, and probability of
death decreased from Level I to III/IV trauma centers ($14,745 to
$9,170, 5.1 to 3.6 days, 3.3% to 2.9%, respectively); for non-
trauma centers, these outcomes were $12,267, 4.6 days, and
2.6%, respectively. CONCLUSION: This is one of few studies to
quantify differences in inpatient costs and outcomes for trau-
matic injury among pediatric patients across levels of injury
severity and trauma center designation, in a multi-payer US
population. Substantial variation was observed for all outcomes
evaluated. These results may help decision makers allocate
resources appropriately.
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OBJECTIVES: To evaluate the cost-effectiveness of Magnetic
Resonance Image-Guided Focused Ultrasound (MRgFUS) com-
pared to alternative treatment options for uterine ﬁbroids from a
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US perspective. METHODS: Techniques of decision analysis and
data from secondary sources were used to develop and estimate
an economic model of the management of uterine ﬁbroids among
premenopausal women. Patients in the model are assumed to
receive ﬁrst-line treatment with MRgFUS, myomectomy, uterine
artery embolization (UAE), hysterectomy, or pain medication
only. Additional rounds of treatment (up to three) for treatment
failure or recurrent ﬁbroids also were incorporated in the model.
The model predicts total costs and quality-adjusted life years
(QALYs) for each strategy over a lifetime horizon. Data on
treatment efﬁcacy and safety were obtained from published and
unpublished studies. Cost data (2005 US$) were estimated from
a large administrative database and supplemented with expert
opinion. Analyses incorporated both direct and indirect (lost
productivity) costs. RESULTS: UAE was associated with the
most discounted QALYs (17.39), followed by MRgFUS (17.36),
myomectomy (17.35), hysterectomy (17.18) and pain manage-
ment (16.70). Pain management was the least costly strategy
($9,200 per patient), followed by hysterectomy ($19,800),
MRgFUS ($27,300), UAE ($28,900), and myomectomy
($35,100). Incremental cost-effectiveness ratios (cost per QALY
gained) were $21,800 for hysterectomy, $41,400 for MRgFUS,
and $54,200 for UAE; myomectomy was both more costly and
less effective than MRgFUS and UAE (i.e., dominated). Sensitiv-
ity analyses indicated that results are sensitive to MRgFUS recur-
rence rates and procedure costs as well as assumptions about the
quality-of-life decrement following hysterectomy. CONCLU-
SION: Our ﬁndings suggest that, with the exception of myomec-
tomy, currently available treatment options for uterine ﬁbroids
(i.e., hysterectomy, UAE, MRgFUS) are in the range of currently
accepted criteria for cost-effectiveness. Any of them could be the
cost-effective choice, depending on patient preferences and
resource availability.
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of idursulfase (Elaprase) treatment of
people with Mucopolysaccharidosis II in the UK. METHODS:
Mucopolysaccharidosis II (MPS II; also referred to as Hunter’s
Syndrome) is an ultra-orphan lysosomal storage disorder that
reveals itself around the age of 3 years and leads to disabling
clinical manifestations and early death. Enzyme replacement
therapy (ERT) using idursulfase was compared to palliative care,
as no other pharmacological treatment is available. A cost utility
cohort model was developed using utility assumptions drawn
from the literature. Data were derived where possible from the
idursulfase pivotal trial, from published literature and from his-
torical records of the UK MPS Society. Where data was not
available, reasonable assumptions were made, with varying sce-
narios employed as sensitivity analyses. Current palliative care
employs physiotherapy, oxygen and care by parents, but varies
by severity of the disease. This lack of consistent approach to
palliative care meant that no direct cost could be assigned. Due
to little clinical experience, only three disease states were con-
sidered: idursulfase-treated, palliative care, and death. The
maximum time horizon was 15 years to account for the chronic
nature of the disease and to encompass the beneﬁts of idursulfase
treatment, which are be expected to change the course of the
disease over the long term. Costs were calculated from UK 2007
prices. Costs and beneﬁts were discounted annually at 3.5%.
RESULTS: The model showed a discounted incremental cost
effectiveness ratio (ICER) over palliative care of GBP564,692 per
quality adjusted life year (QALY). Sensitivity analyses showed
that the two key drivers of the ICER are quality of life and
mortality. CONCLUSION: Although high, the ICER for MPS II
is consistent with other orphan diseases treated with ERT, such as
Gaucher’s and Fabry’s diseases.
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OBJECTIVES: The Fleetwood model is a holistic approach to
structured pharmaceutical care in the nursing home setting. It has
been adapted for use in the UK and is currently being tested in NI
in a randomised controlled trial. The aim of this study was to use
MDWS to provide estimates of resource usage for inclusion in a
cost model. METHODS: Pharmacists providing the adapted
Fleetwood pharmaceutical care service to nursing home residents
completed an activity classiﬁcation sheet (previously developed
and piloted), comprising 15 main categories. This provided infor-
mation on the type of activity undertaken, time taken and
whether it was related to ‘cycle 1’ (initial pharmaceutical care
plan development) or subsequent cycles. Data reported is for 9
pharmacists during the ﬁrst three cycles carried out in 11 inter-
vention homes. RESULTS: Actual resource utilisation was sig-
niﬁcantly different to estimates used to obtain funding. It was
estimated that ‘cycle 1’ would involve 3 hours of pharmacist time
per nursing home resident and last 30 days, and that each
subsequent cycle would involve 1 hour per month (30 days)
per resident. The actual total time spent was 46.1% of that
estimated, and the average cost per resident was 39%
(92.31  33.83 vs. 236.74  15.70). Signiﬁcantly more time
than estimated was required to complete a cycle; the longest cycle
length occurred in cycle 1 (170 days) with 30.2 hrs  5.16 spent
in each home delivering the service to 15.7  2.2 residents.
Semi-professional or non-professional activity accounted for
71.5% of total time in cycle 1. CONCLUSION: MDWS enabled
a more accurate picture of pharmacist activities and estimates of
time input for inclusion in the cost model. This information is
important in planning service development and delivery, as non-
or semi-professional activities could be delegated to pharmacy
support staff.
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OBJECTIVES: The practice of drug keeping in homes and self
medication is well recognised problem. The aim of our work was
to compare pharmacotherapeutical and pharmacoepidemiologi-
cal aspects of drug home cabinets in two countries with different
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